BioStem Technologies to Present at the Centri Capital Conference

Rhea-AI Summary

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, has announced its participation in the upcoming Centri Capital Conference at Nasdaq headquarters in New York City.

CEO Jason Matuszewski will deliver a presentation on April 22, 2025, at 10:30 AM ET and conduct one-on-one meetings with interested parties. The company's core technology, BioREtain®, is their proprietary processing method focused on maintaining growth factors and preserving tissue structure.

BioStem's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC® products, all processed at their FDA registered and AATB accredited facility in Pompano Beach, Florida. The company maintains quality management systems and standard operating procedures accredited by the American Association of Tissue Banks, following current Good Tissue Practices and Good Manufacturing Processes.

The presentation will be webcast at 10:30 AM ET on April 22, 2025

POMPANO BEACH, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive Officer, Jason Matuszewski, will be presenting and holding one-on-one meetings at the upcoming Centri Capital Conference on April 22, 2025, taking place at the Nasdaq headquarters in New York City.

BioStem Technologies Presentation Access:

• Presenter: Jason Matuszewski, Chief Executive Officer
• Date: Tuesday, April 22, 2025
• Time: 10:30 AM ET
• Webcast Link & Archive: HERE
• 1-on-1 Meeting Request: adam@holdsworthco.com
  

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on Twitter and LinkedIn.

About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain^® processing method. BioREtain^® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap²™, VENDAJE^®, VENDAJE AC^®, and VENDAJE OPTIC^®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn.

BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStem Technologies

Investor Relations
Adam Holdsworth
Adam@holdsworthco.com
917-497-9287

FAQ

When and where is BioStem Technologies (BSEM) presenting at the Centri Capital Conference?

BioStem Technologies (BSEM) is presenting on Tuesday, April 22, 2025, at 10:30 AM ET at the Nasdaq headquarters in New York City.

What products are in BioStem Technologies' (BSEM) current portfolio?

BioStem's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®, all of which are placental allografts for advanced wound care.

What is BioStem Technologies' (BSEM) BioREtain® processing method?

BioREtain® is BioStem's proprietary processing method developed for maintaining growth factors and preserving tissue structure in advanced wound care products.

What certifications does BioStem Technologies' (BSEM) manufacturing facility have?

BioStem's Pompano Beach facility is FDA registered and AATB accredited, following cGTP and cGMP standards with AATB-accredited quality management systems.

How can investors follow BioStem Technologies' (BSEM) latest developments?

Investors can sign up for the company's email distribution list, follow them on Twitter (@BSEM_Tech), LinkedIn, or contact investor relations at adam@holdsworthco.com.